Marker Therapeutics Q1 2024 Update

TL;DR

Marker Therapeutics (MRKR) filed its Q1 2024 10-Q, showing financial updates and past name changes.

AI Summary

Marker Therapeutics, Inc. reported its first quarter 2024 results, ending March 31, 2024. The company's financial statements show changes in common stock and additional paid-in capital. Marker Therapeutics previously operated under the names TAPIMMUNE INC. and GENEMAX CORP.

Why It Matters

This filing provides insight into Marker Therapeutics' financial health and corporate history, which can influence investor decisions.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Marker Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

• 8900000 — Common Stock Value (Value related to common stock for the fiscal year ending 12/31/2024)
• 8900000 — Additional Paid-in Capital (Value related to additional paid-in capital for the fiscal year ending 12/31/2024)

Key Players & Entities

• Marker Therapeutics, Inc. (company) — Filer
• 20240331 (date) — Reporting Period End Date
• TAPIMMUNE INC. (company) — Former Company Name
• GENEMAX CORP (company) — Former Company Name
• 4551 KENNEDY COMMERCE DR. (location) — Business Address
• HOUSTON (location) — Business City
• 77032 (location) — Business Zip Code

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share MRKR The Nasdaq Stock Mar
• $250,000 — Corporation ("FDIC") insured limits of $250,000. As of March 31, 2024, the Company had

Filing Documents

• mrkr-20240331x10q.htm (10-Q) — 909KB
• mrkr-20240331xex31d1.htm (EX-31.1) — 13KB
• mrkr-20240331xex31d2.htm (EX-31.2) — 13KB
• mrkr-20240331xex32d1.htm (EX-32.1) — 7KB
• mrkr-20240331xex32d2.htm (EX-32.2) — 7KB
• mrkr-20240331x10q001.jpg (GRAPHIC) — 12KB
• mrkr-20240331x10q002.jpg (GRAPHIC) — 46KB
• mrkr-20240331x10q003.jpg (GRAPHIC) — 34KB
• 0001410578-24-000865.txt ( ) — 4586KB
• mrkr-20240331.xsd (EX-101.SCH) — 38KB
• mrkr-20240331_cal.xml (EX-101.CAL) — 33KB
• mrkr-20240331_def.xml (EX-101.DEF) — 169KB
• mrkr-20240331_lab.xml (EX-101.LAB) — 304KB
• mrkr-20240331_pre.xml (EX-101.PRE) — 260KB
• mrkr-20240331x10q_htm.xml (XML) — 554KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION 1 Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets As of March 31, 2024 and December 31, 2023 1 Condensed Consolidated Statements of Operations for the three months ended March 31, 2024 and 2023 2 Condensed Consolidated Statements of Stockholders' Equity for the three months ended March 31, 2024 and 2023 3 Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and 2023 4 Notes to Condensed Consolidated Financial Statements 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations. 16 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk. 24 Item 4.

Controls and Procedures

Controls and Procedures. 24

– OTHER INFORMATION

PART II – OTHER INFORMATION 25 Item 1. Legal Proceedings. 25 Item 1A. Risk Factors. 25 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. 25 Item 3. Defaults Upon Senior Securities. 25 Item 4. Mine Safety Disclosure. 25 Item 5. Other Information. 25 Item 6. Exhibits. 26

Signatures

Signatures 28 Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statement s

Item 1. Financial Statement s MARKER THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) March 31, December 31, 2024 2023 ASSETS Current assets: Cash and cash equivalents $ 11,323,428 $ 15,111,450 Prepaid expenses and deposits 917,009 988,126 Other receivables 1,851,462 1,027,815 Total current assets 14,091,899 17,127,391 Total assets $ 14,091,899 $ 17,127,391 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable and accrued liabilities $ 1,949,700 $ 1,745,193 Related party payable 353,965 1,329,655 Total current liabilities 2,303,665 3,074,848 Total liabilities 2,303,665 3,074,848 Stockholders' equity: Preferred stock, $ 0.001 par value, 5 million shares authorized, 0 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively — — Common stock, $ 0.001 par value, 30 million shares authorized, 8.9 million shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively (see Note 9) 8,910 8,891 Additional paid-in capital 450,458,009 450,329,515 Accumulated deficit ( 438,678,685 ) ( 436,285,863 ) Total stockholders' equity 11,788,234 14,052,543 Total liabilities and stockholders' equity $ 14,091,899 $ 17,127,391 See accompanying notes to these unaudited condensed consolidated financial statements. 1 Table of Contents MARKER THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) For the Three Months Ended March 31, 2024 2023 Revenues: Grant income $ 1,244,061 $ 1,234,336 Total revenues 1,244,061 1,234,336 Operating expenses: Research and development 2,575,015 3,376,497 General and administrative 1,218,063 2,167,318 Total operating expenses 3,793,078 5,543,815 Loss from operations ( 2,549,017 ) ( 4,309,479 ) Other income (expenses): Interest income 156,195 84,654 Loss from continuing operations ( 2,3

View Full Filing

View this 10-Q filing on SEC EDGAR